FDA Panel Will Review Rotarix Pneumonia-Related Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency analysis of GlaxoSmithKline rotavirus vaccine showed more pneumonia-related deaths and convulsions in clinical studies.
You may also be interested in...
FDA Panel Votes To Clear GlaxoSmithKline Rotavirus Vaccine For Approval
GSK’s Rotarix gets nod from FDA’s Vaccines and Related Biological Products Advisory Committee.
FDA Panel Votes To Clear GlaxoSmithKline Rotavirus Vaccine For Approval
GSK’s Rotarix gets nod from FDA’s Vaccines and Related Biological Products Advisory Committee.
GSK’s Rotarix Gets FDA Vaccines Advisory Committee Review
Feb. 20 meeting to focus on product safety for Rotarix, which would have a shorter dosing schedule than Merck’s RotaTeq and target more virus types.